Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

A quality improvement project aimed at adapting primary care to ensure the delivery of evidence-based psychotherapy for adult anxiety.

Williams MD, Sawchuk CN, Shippee ND, Somers KJ, Berg SL, Mitchell JD, Mattson AB, Katzelnick DJ.

BMJ Open Qual. 2018 Jan 9;7(1):e000066. doi: 10.1136/bmjoq-2017-000066. eCollection 2018.

2.

Manganese and neurobehavioral impairment. A preliminary risk assessment.

Park RM, Berg SL.

Neurotoxicology. 2018 Jan;64:159-165. doi: 10.1016/j.neuro.2017.08.003. Epub 2017 Aug 10.

3.

Integrated tumor and germline whole-exome sequencing identifies mutations in MAPK and PI3K pathway genes in an adolescent with rosette-forming glioneuronal tumor of the fourth ventricle.

Lin FY, Bergstrom K, Person R, Bavle A, Ballester LY, Scollon S, Raesz-Martinez R, Jea A, Birchansky S, Wheeler DA, Berg SL, Chintagumpala MM, Adesina AM, Eng C, Roy A, Plon SE, Parsons DW.

Cold Spring Harb Mol Case Stud. 2016 Sep;2(5):a001057. doi: 10.1101/mcs.a001057.

4.

Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors.

Parsons DW, Roy A, Yang Y, Wang T, Scollon S, Bergstrom K, Kerstein RA, Gutierrez S, Petersen AK, Bavle A, Lin FY, López-Terrada DH, Monzon FA, Hicks MJ, Eldin KW, Quintanilla NM, Adesina AM, Mohila CA, Whitehead W, Jea A, Vasudevan SA, Nuchtern JG, Ramamurthy U, McGuire AL, Hilsenbeck SG, Reid JG, Muzny DM, Wheeler DA, Berg SL, Chintagumpala MM, Eng CM, Gibbs RA, Plon SE.

JAMA Oncol. 2016 Jan 28. doi: 10.1001/jamaoncol.2015.5699. [Epub ahead of print]

5.

The Pharmacogenomics of Vincristine-Induced Neuropathy: On Pins and Needles.

Berg SL, Parsons DW.

JAMA Oncol. 2015 Oct;1(7):975-6. doi: 10.1001/jamaoncol.2015.1173. No abstract available.

PMID:
26181361
6.

Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients.

Scollon S, Bergstrom K, Kerstein RA, Wang T, Hilsenbeck SG, Ramamurthy U, Gibbs RA, Eng CM, Chintagumpala MM, Berg SL, McCullough LB, McGuire AL, Plon SE, Parsons DW.

Genome Med. 2014 Sep 17;6(9):69. doi: 10.1186/s13073-014-0069-3. eCollection 2014.

7.

Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group.

Thompson P, Wheeler HE, Delaney SM, Lorier R, Broeckel U, Devidas M, Reaman GH, Scorsone K, Sung L, Dolan ME, Berg SL.

Cancer Chemother Pharmacol. 2014 Oct;74(4):831-8. doi: 10.1007/s00280-014-2535-4. Epub 2014 Aug 14.

8.

Pharmacokinetics of doxorubicin in pregnant women.

Ryu RJ, Eyal S, Kaplan HG, Akbarzadeh A, Hays K, Puhl K, Easterling TR, Berg SL, Scorsone KA, Feldman EM, Umans JG, Miodovnik M, Hebert MF.

Cancer Chemother Pharmacol. 2014 Apr;73(4):789-97. doi: 10.1007/s00280-014-2406-z. Epub 2014 Feb 15.

9.

Optimizing otoscopy competency in audiology students through supplementary otoscopy training.

Kaf WA, Masterson CG, Dion N, Berg SL, Abdelhakiem MK.

J Am Acad Audiol. 2013 Oct;24(9):859-66. doi: 10.3766/jaaa.24.9.9.

PMID:
24224992
10.

A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: a Pediatric Brain Tumor Consortium study.

Blaney SM, Tagen M, Onar-Thomas A, Berg SL, Gururangan S, Scorsone K, Su J, Goldman S, Kieran MW, Kun L, Boyett J, Stewart C.

Pediatr Blood Cancer. 2013 Apr;60(4):627-32. doi: 10.1002/pbc.24309. Epub 2012 Sep 21.

11.

Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.

Muscal JA, Scorsone KA, Zhang L, Ecsedy JA, Berg SL.

Invest New Drugs. 2013 Feb;31(1):39-45. doi: 10.1007/s10637-012-9831-9. Epub 2012 Jun 6.

12.

Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates.

Muscal JA, Sun Y, Nuchtern JG, Dauser RC, McGuffey LH, Gibson BW, Berg SL.

Cancer Chemother Pharmacol. 2012 Apr;69(4):943-7. doi: 10.1007/s00280-011-1781-y. Epub 2011 Nov 23.

13.

A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.

Warren KE, Gururangan S, Geyer JR, McLendon RE, Poussaint TY, Wallace D, Balis FM, Berg SL, Packer RJ, Goldman S, Minturn JE, Pollack IF, Boyett JM, Kun LE.

J Neurooncol. 2012 Feb;106(3):643-9. doi: 10.1007/s11060-011-0709-z. Epub 2011 Oct 4.

14.

Educational paper. The development of new therapies for pediatric oncology.

Horton TM, Berg SL.

Eur J Pediatr. 2011 May;170(5):555-9. doi: 10.1007/s00431-010-1374-5. Epub 2010 Dec 30. Review.

PMID:
21190039
15.

Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report.

Berg SL, Cairo MS, Russell H, Ayello J, Ingle AM, Lau H, Chen N, Adamson PC, Blaney SM.

J Clin Oncol. 2011 Jan 20;29(3):316-23. doi: 10.1200/JCO.2010.30.8387. Epub 2010 Dec 13.

16.

Reasons for participation in optional pharmacokinetic studies in children with cancer: a Children's Oncology Group phase 1 consortium study.

Berg SL, Winick N, Ingle AM, Adamson PC, Blaney SM.

Pediatr Blood Cancer. 2010 Jul 15;55(1):119-22. doi: 10.1002/pbc.22529.

17.

Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity.

Horton TM, Jenkins G, Pati D, Zhang L, Dolan ME, Ribes-Zamora A, Bertuch AA, Blaney SM, Delaney SL, Hegde M, Berg SL.

Mol Cancer Ther. 2009 Aug;8(8):2232-42. doi: 10.1158/1535-7163.MCT-09-0142. Epub 2009 Aug 11.

18.

Please don't call my mom: pediatric consent and confidentiality.

Bruce CR, Berg SL, McGuire AL.

Clin Pediatr (Phila). 2009 Apr;48(3):243-6. doi: 10.1177/0009922808328542. Epub 2008 Dec 11. No abstract available.

PMID:
19074356
19.

When too much is just enough: what do oncologists tell parents?

Berg SL.

Pediatr Blood Cancer. 2009 Apr;52(4):437-8. doi: 10.1002/pbc.21871. Review. No abstract available.

PMID:
19058206
20.

Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates.

Kilburn LB, Bonate PL, Blaney SM, McGuffey L, Nuchtern JG, Dauser R, Thompson P, Gibson BW, Berg SL.

Cancer Chemother Pharmacol. 2009 Jul;64(2):335-40. doi: 10.1007/s00280-008-0875-7. Epub 2008 Nov 29.

PMID:
19043710
21.

Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study.

Thompson PA, Rosner GL, Matthay KK, Moore TB, Bomgaars LR, Ellis KJ, Renbarger J, Berg SL.

Cancer Chemother Pharmacol. 2009 Jul;64(2):243-51. doi: 10.1007/s00280-008-0854-z. Epub 2008 Nov 20.

PMID:
19020877
22.

Characteristics and outcome of pediatric patients enrolled in phase I oncology trials.

Kim A, Fox E, Warren K, Blaney SM, Berg SL, Adamson PC, Libucha M, Byrley E, Balis FM, Widemann BC.

Oncologist. 2008 Jun;13(6):679-89. doi: 10.1634/theoncologist.2008-0046.

23.

Ethical challenges in cancer research in children.

Berg SL.

Oncologist. 2007 Nov;12(11):1336-43.

24.

Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.

Horton TM, Thompson PA, Berg SL, Adamson PC, Ingle AM, Dolan ME, Delaney SM, Hedge M, Weiss HL, Wu MF, Blaney SM; Children's Oncology Group Study.

J Clin Oncol. 2007 Nov 1;25(31):4922-8.

PMID:
17971589
25.

Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study.

Adams DM, Zhou T, Berg SL, Bernstein M, Neville K, Blaney SM; Children's Oncology Group.

Pediatr Blood Cancer. 2008 Mar;50(3):549-53.

PMID:
17941066
26.

Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis.

Bernardi RJ, Bomgaars L, Fox E, Balis FM, Egorin MJ, Lagattuta TF, Aikin A, Whitcomb P, Renbarger J, Lieberman FS, Berg SL, Blaney SM.

Cancer Chemother Pharmacol. 2008 Jul;62(2):355-61. Epub 2007 Oct 2.

PMID:
17909804
27.

Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.

Jacob E, Scorsone K, Blaney SM, D'Argenio DZ, Berg SL.

Pediatr Blood Cancer. 2008 Apr;50(4):757-60.

28.

Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates.

Stapleton SL, Thompson PA, Ou CN, Berg SL, McGuffey L, Gibson B, Blaney SM.

Cancer Chemother Pharmacol. 2008 Apr;61(4):647-52. Epub 2007 May 31.

PMID:
17541590
29.

Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia.

Thompson PA, Murry DJ, Rosner GL, Lunagomez S, Blaney SM, Berg SL, Camitta BM, Dreyer ZE, Bomgaars LR.

Cancer Chemother Pharmacol. 2007 May;59(6):847-53. Epub 2006 Nov 29.

PMID:
17136402
30.

Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates.

Berg SL, Brueckner C, Nuchtern JG, Dauser R, McGuffey L, Blaney SM.

Cancer Chemother Pharmacol. 2007 May;59(6):743-7. Epub 2006 Sep 5.

PMID:
16953392
31.

Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.

Horton TM, Gannavarapu A, Blaney SM, D'Argenio DZ, Plon SE, Berg SL.

Cancer Chemother Pharmacol. 2006 Jul;58(1):13-23. Epub 2005 Nov 15.

PMID:
16292537
32.
33.

Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates.

Berg SL, Bonate PL, Nuchtern JG, Dauser R, McGuffey L, Bernacky B, Blaney SM.

Clin Cancer Res. 2005 Aug 15;11(16):5981-3.

34.

Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group.

Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, Billett A, Kurtzberg J, Reaman G, Gaynon P, Whitlock J, Krailo M, Harris MB; Children's Oncology Group.

J Clin Oncol. 2005 May 20;23(15):3376-82.

PMID:
15908649
35.

Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study.

Horton TM, Blaney SM, Langevin AM, Kuhn J, Kamen B, Berg SL, Bernstein M, Weitman S.

Clin Cancer Res. 2005 Mar 1;11(5):1884-9.

36.

Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.

Cairo MS, Davenport V, Bessmertny O, Goldman SC, Berg SL, Kreissman SG, Laver J, Shen V, Secola R, van de Ven C, Reaman GH.

Br J Haematol. 2005 Jan;128(1):49-58.

PMID:
15606549
37.

Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015).

Blaney SM, Bernstein M, Neville K, Ginsberg J, Kitchen B, Horton T, Berg SL, Krailo M, Adamson PC.

J Clin Oncol. 2004 Dec 1;22(23):4804-9. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248.

PMID:
15570082
38.

Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer.

Chintagumpala M, Blaney SM, Bomgaars LR, Aleksic A, Kuttesch JF, Klenke RA, Berg SL.

J Clin Oncol. 2004 Nov 1;22(21):4394-400.

PMID:
15514381
39.

Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis.

Bomgaars L, Geyer JR, Franklin J, Dahl G, Park J, Winick NJ, Klenke R, Berg SL, Blaney SM.

J Clin Oncol. 2004 Oct 1;22(19):3916-21.

PMID:
15459213
40.

Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates.

Berg SL, Aleksic A, McGuffey L, Dauser R, Nuchtern J, Bernacky B, Blaney SM.

Cancer Chemother Pharmacol. 2004 Aug;54(2):127-30. Epub 2004 May 18.

PMID:
15150671
41.

Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates.

Neville K, Parise RA, Thompson P, Aleksic A, Egorin MJ, Balis FM, McGuffey L, McCully C, Berg SL, Blaney SM.

Clin Cancer Res. 2004 Apr 1;10(7):2525-9.

42.

Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates.

Berg SL, Stone J, Xiao JJ, Chan KK, Nuchtern J, Dauser R, McGuffey L, Thompson P, Blaney SM.

Cancer Chemother Pharmacol. 2004 Jul;54(1):85-8. Epub 2004 Mar 23.

PMID:
15042312
43.

Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates.

Thompson PA, Berg SL, Aleksic A, Kerr JZ, McGuffey L, Dauser R, Nuchtern JG, Hausheer F, Blaney SM.

Cancer Chemother Pharmacol. 2004 Jun;53(6):527-32. Epub 2004 Mar 2.

PMID:
14997342
44.
45.

Pharmacokinetics of intrathecal gemcitabine in nonhuman primates.

Egorin MJ, Zuhowski EG, McCully CM, Blaney SM, Kerr JZ, Berg SL, Balis FM.

Clin Cancer Res. 2002 Jul;8(7):2437-42.

46.

The development of camptothecin analogs in childhood cancers.

Bomgaars L, Berg SL, Blaney SM.

Oncologist. 2001;6(6):506-16. Review.

47.

Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates.

Kerr JZ, Berg SL, Dauser R, Nuchtern J, Egorin MJ, McGuffey L, Aleksic A, Blaney S.

Cancer Chemother Pharmacol. 2001 May;47(5):411-4.

PMID:
11391856
48.

A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.

Blaney S, Berg SL, Pratt C, Weitman S, Sullivan J, Luchtman-Jones L, Bernstein M.

Clin Cancer Res. 2001 Jan;7(1):32-7.

49.

Phase II trial of pyrazoloacridine in children with solid tumors: a Pediatric Oncology Group phase II study.

Berg SL, Blaney SM, Sullivan J, Bernstein M, Dubowy R, Harris MB; Pediatric Oncology Group.

J Pediatr Hematol Oncol. 2000 Nov-Dec;22(6):506-9.

50.

Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and analogues in nonhuman primates.

Long L, Berg SL, Roy SK, McCully CL, Song-Yoo HW, Moschel RC, Balis FM, Dolan ME.

Clin Cancer Res. 2000 Sep;6(9):3662-9.

Supplemental Content

Support Center